Meet us at the ECCI Conference 2024!
Aidian is attending the ECCI (European Congenital Cytomegalovirus Initiative) 2024 Conference organised 9-11 October 2024 at the Naturalis Biodiversity Center in Leiden, The Netherlands. ECCI, a transdisciplinary group of experts, provides guidance on the management of congenital cytomegalovirus infection in the prenatal, neonatal, and postnatal stages.
Cytomegalovirus (CMV) can pass from mothers to babies during pregnancy. When a baby is born with CMV it is called congenital CMV (cCMV) and about 1 out of every 200 babies is born with cCMV infection. Diagnosis of congenital infection requires detection of the virus in the first 2-3 weeks of life. Early detection of cCMV is vital for guiding newborns appropriate treatment and improving patient outcomes. 1-3
The Alethia CMV molecular assay from Meridian Bioscience detects CMV from saliva, an easy to collect newborns sample type for testing. Alethia CMV is easy to perform and provides quick and accurate results within 1 hour.
Aidian is the proud distributor of Meridian Bioscience's complete portfolio.
Visit Aidian's and Meridian Bioscience's joint booth to learn more about the Alethia CMV and on how CMV testing increases diagnostic certainty and guides appropriate patient management.
We look forward to meeting you in Leiden!
References
- Centres for Disease Control and Prevention (CDC). CMV in Newborns. Available at: https://www.cdc.gov/cytomegalovirus/congenital-infection/index.html Accessed 24 September 2024.
- Centres for Disease Control and Prevention (CDC). About Cytomegalovirus. Available at: https://www.cdc.gov/cytomegalovirus/about/index.html Accessed 24 September 2024.
- Leruez-Ville, Marianne et al. Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI). The Lancet Regional Health – Europe, Volume 40, 2024. https://doi.org/10.1016/j.lanepe.2024.100892